BSPM - Biostar Pharmaceuticals, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1600
0.0000 (0.00%)
At close: 11:22AM EDT
Stock chart is not supported by your current browser
Previous Close0.1600
Open0.1600
BidN/A x N/A
AskN/A x N/A
Day's Range0.1600 - 0.1600
52 Week Range0.1300 - 3.4700
Volume1
Avg. Volume2,225
Market Cap421,950
Beta (3Y Monthly)3.48
PE Ratio (TTM)0.47
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • ACCESSWIRE10 months ago

    Today's Research Reports on Stocks to Watch: Biostar Pharmaceuticals and ABIOMED

    NEW YORK, NY / ACCESSWIRE / July 27, 2018 / Biostar shares saw a rebound on Thursday, closing the day up over 27% after falling on Wednesday when Wall Street learned the company had received a delisting ...

  • ACCESSWIRE10 months ago

    Biostar Pharmaceuticals Received Nasdaq Delisting Notification

    XIANYANG, CHINA / ACCESSWIRE / July 25, 2018 / Biostar Pharmaceuticals, Inc. (BSPM) (''the Company''), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China, announced today that on July 19, 2018 it received a notification letter from Nasdaq Listing Qualifications (''Nasdaq'') advising the Company that following review of the Company's plan of compliance, the Nasdaq staff determined to delist the Company's common stock from the Nasdaq Capital Market. The delisting notification stated that such delisting would be effective at the opening of business on July 30, 2018 unless the Company requests an appeal of the delisting determination. As previously disclosed, the Company was cited for failures to comply with this Listing Rule because it had not filed its Form 10-K for the year ended December 31, 2017 and its Form 10-Q for the period ended March 31, 2018.

  • ACCESSWIRElast year

    Biostar Announces Receipt of Nasdaq Continued Listing Deficiency Notice

    XIANYANG, CHINA / ACCESSWIRE / May 30, 2018 / Biostar Pharmaceuticals, Inc. (BSPM) ("the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China, announced today that on May 23, 2018 it received a notification letter from Nasdaq Listing Qualifications ("Nasdaq") advising the Company that, since it had not filed its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2018, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) for continued listing. As previously disclosed, on April 19, 2018, the Company received a notification letter from Nasdaq advising the Company that, since it had not filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2017, the Company was not in compliance with Nasdaq Listing Rules.